COVID-19 among Indonesian ENT specialist and resident after second dose of Sinovac vaccination

Indra Zachreini; Jenny Bashiruddin; Susyana Tamin; Harim Priyono; Natasha Supartono; Anggina Diksita; Respati Wulansari Ranakusuma; Yussy Afriani Dewi; Sagung Rai Indrasari; Nyilo Purnami; Tengku Siti Hajar Haryuna; Juliandi Harahap; Eka Savitri; Tjandra Manukbua; Ika Dewi Mayangsari

doi:10.12688/f1000research.126527.1

COVID-19 among Indonesian ENT specialist and resident after second dose of Sinovac vaccination

Indra Zachreini, Jenny Bashiruddin, Susyana Tamin, Harim Priyono, Natasha Supartono, Anggina Diksita, Respati Wulansari Ranakusuma, Yussy Afriani Dewi, Sagung Rai Indrasari, Nyilo Purnami, Tengku Siti Hajar Haryuna, Juliandi Harahap, Eka Savitri, Tjandra Manukbua, Ika Dewi Mayangsari

Department of Ear, Nose, and Throat Clinic (ENT)

Research output: Contribution to journal › Article › peer-review

Abstract

Background: The purpose of this study was to obtain data on the prevalence of specialist doctors and Otorhinolaryngology-Head and Neck Surgery (ORL-HNS) residents in Indonesia who suffered from Coronavirus disease 2019 (COVID-19) after receiving the second dose of COVID-19 vaccination using the Sinovac vaccine (CoronaVac) and the length of time infected with COVID-19 after the second Sinovac vaccination. Methods: We performed a descriptive observational study, using a cross-sectional design. Data collection took place between August 2021 and October 2021. The respondents in this study included specialist doctors and ORL-HNS residents who worked in various hospitals in Indonesia who had received the second dose of the Sinovac vaccination. Data collection was performed by means of Self-reporting Online Survey Platform (Google Form). Results: This study included 1,530 respondents, and 54.2% of respondents were women. Respondents consisted of 68.6% ORL-HNS doctors and the rest were residents with an average age of 41.46 years old. The distance between the first and second doses of Sinovac was mostly under one month, which was 71.3% of the respondents. A total of 76.3% of respondents did not have co-morbid diseases. Based on this study, 16.9% of respondents suffered from COVID-19 after the second dose of Sinovac vaccination. The length of time suffering from COVID-19 after the second Sinovac vaccination was 3-6 months (9.7%). Conclusions: Based on this study, 16.9% of respondents suffered from COVID-19 after receiving the second Sinovac vaccination and 9.7% suffered from COVID-19 after 3-6 months of Sinovac vaccination.

Original language	English
Article number	1454
Journal	F1000Research
Volume	11
DOIs	https://doi.org/10.12688/f1000research.126527.1
Publication status	Published - 2022

Keywords

Covid 19
Sinovac vaccine
Vaccination

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.12688/f1000research.126527.1

Cite this

Zachreini, I., Bashiruddin, J., Tamin, S., Priyono, H., Supartono, N., Diksita, A., Ranakusuma, R. W., Dewi, Y. A., Indrasari, S. R., Purnami, N., Haryuna, T. S. H., Harahap, J., Savitri, E., Manukbua, T., & Mayangsari, I. D. (2022). COVID-19 among Indonesian ENT specialist and resident after second dose of Sinovac vaccination. F1000Research, 11, Article 1454. https://doi.org/10.12688/f1000research.126527.1

@article{e874a0c7fad84b41ae26cfbf1555c1f6,

title = "COVID-19 among Indonesian ENT specialist and resident after second dose of Sinovac vaccination",

abstract = "Background: The purpose of this study was to obtain data on the prevalence of specialist doctors and Otorhinolaryngology-Head and Neck Surgery (ORL-HNS) residents in Indonesia who suffered from Coronavirus disease 2019 (COVID-19) after receiving the second dose of COVID-19 vaccination using the Sinovac vaccine (CoronaVac) and the length of time infected with COVID-19 after the second Sinovac vaccination. Methods: We performed a descriptive observational study, using a cross-sectional design. Data collection took place between August 2021 and October 2021. The respondents in this study included specialist doctors and ORL-HNS residents who worked in various hospitals in Indonesia who had received the second dose of the Sinovac vaccination. Data collection was performed by means of Self-reporting Online Survey Platform (Google Form). Results: This study included 1,530 respondents, and 54.2% of respondents were women. Respondents consisted of 68.6% ORL-HNS doctors and the rest were residents with an average age of 41.46 years old. The distance between the first and second doses of Sinovac was mostly under one month, which was 71.3% of the respondents. A total of 76.3% of respondents did not have co-morbid diseases. Based on this study, 16.9% of respondents suffered from COVID-19 after the second dose of Sinovac vaccination. The length of time suffering from COVID-19 after the second Sinovac vaccination was 3-6 months (9.7%). Conclusions: Based on this study, 16.9% of respondents suffered from COVID-19 after receiving the second Sinovac vaccination and 9.7% suffered from COVID-19 after 3-6 months of Sinovac vaccination.",

keywords = "Covid 19, Sinovac vaccine, Vaccination",

author = "Indra Zachreini and Jenny Bashiruddin and Susyana Tamin and Harim Priyono and Natasha Supartono and Anggina Diksita and Ranakusuma, {Respati Wulansari} and Dewi, {Yussy Afriani} and Indrasari, {Sagung Rai} and Nyilo Purnami and Haryuna, {Tengku Siti Hajar} and Juliandi Harahap and Eka Savitri and Tjandra Manukbua and Mayangsari, {Ika Dewi}",

note = "Funding Information: The author(s) declared that no grants were involved in supporting this work. Publisher Copyright: Copyright: {\textcopyright} 2022 Zachreini I et al.",

year = "2022",

doi = "10.12688/f1000research.126527.1",

language = "English",

volume = "11",

journal = "F1000Research",

issn = "2046-1402",

publisher = "F1000 Research Ltd",

}

Zachreini, I, Bashiruddin, J , Tamin, S , Priyono, H, Supartono, N, Diksita, A, Ranakusuma, RW, Dewi, YA, Indrasari, SR, Purnami, N, Haryuna, TSH, Harahap, J, Savitri, E, Manukbua, T & Mayangsari, ID 2022, 'COVID-19 among Indonesian ENT specialist and resident after second dose of Sinovac vaccination', F1000Research, vol. 11, 1454. https://doi.org/10.12688/f1000research.126527.1

TY - JOUR

T1 - COVID-19 among Indonesian ENT specialist and resident after second dose of Sinovac vaccination

AU - Zachreini, Indra

AU - Bashiruddin, Jenny

AU - Tamin, Susyana

AU - Priyono, Harim

AU - Supartono, Natasha

AU - Diksita, Anggina

AU - Ranakusuma, Respati Wulansari

AU - Dewi, Yussy Afriani

AU - Indrasari, Sagung Rai

AU - Purnami, Nyilo

AU - Haryuna, Tengku Siti Hajar

AU - Harahap, Juliandi

AU - Savitri, Eka

AU - Manukbua, Tjandra

AU - Mayangsari, Ika Dewi

PY - 2022

Y1 - 2022

N2 - Background: The purpose of this study was to obtain data on the prevalence of specialist doctors and Otorhinolaryngology-Head and Neck Surgery (ORL-HNS) residents in Indonesia who suffered from Coronavirus disease 2019 (COVID-19) after receiving the second dose of COVID-19 vaccination using the Sinovac vaccine (CoronaVac) and the length of time infected with COVID-19 after the second Sinovac vaccination. Methods: We performed a descriptive observational study, using a cross-sectional design. Data collection took place between August 2021 and October 2021. The respondents in this study included specialist doctors and ORL-HNS residents who worked in various hospitals in Indonesia who had received the second dose of the Sinovac vaccination. Data collection was performed by means of Self-reporting Online Survey Platform (Google Form). Results: This study included 1,530 respondents, and 54.2% of respondents were women. Respondents consisted of 68.6% ORL-HNS doctors and the rest were residents with an average age of 41.46 years old. The distance between the first and second doses of Sinovac was mostly under one month, which was 71.3% of the respondents. A total of 76.3% of respondents did not have co-morbid diseases. Based on this study, 16.9% of respondents suffered from COVID-19 after the second dose of Sinovac vaccination. The length of time suffering from COVID-19 after the second Sinovac vaccination was 3-6 months (9.7%). Conclusions: Based on this study, 16.9% of respondents suffered from COVID-19 after receiving the second Sinovac vaccination and 9.7% suffered from COVID-19 after 3-6 months of Sinovac vaccination.

AB - Background: The purpose of this study was to obtain data on the prevalence of specialist doctors and Otorhinolaryngology-Head and Neck Surgery (ORL-HNS) residents in Indonesia who suffered from Coronavirus disease 2019 (COVID-19) after receiving the second dose of COVID-19 vaccination using the Sinovac vaccine (CoronaVac) and the length of time infected with COVID-19 after the second Sinovac vaccination. Methods: We performed a descriptive observational study, using a cross-sectional design. Data collection took place between August 2021 and October 2021. The respondents in this study included specialist doctors and ORL-HNS residents who worked in various hospitals in Indonesia who had received the second dose of the Sinovac vaccination. Data collection was performed by means of Self-reporting Online Survey Platform (Google Form). Results: This study included 1,530 respondents, and 54.2% of respondents were women. Respondents consisted of 68.6% ORL-HNS doctors and the rest were residents with an average age of 41.46 years old. The distance between the first and second doses of Sinovac was mostly under one month, which was 71.3% of the respondents. A total of 76.3% of respondents did not have co-morbid diseases. Based on this study, 16.9% of respondents suffered from COVID-19 after the second dose of Sinovac vaccination. The length of time suffering from COVID-19 after the second Sinovac vaccination was 3-6 months (9.7%). Conclusions: Based on this study, 16.9% of respondents suffered from COVID-19 after receiving the second Sinovac vaccination and 9.7% suffered from COVID-19 after 3-6 months of Sinovac vaccination.

KW - Covid 19

KW - Sinovac vaccine

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85152918811&partnerID=8YFLogxK

U2 - 10.12688/f1000research.126527.1

DO - 10.12688/f1000research.126527.1

M3 - Article

AN - SCOPUS:85152918811

SN - 2046-1402

VL - 11

JO - F1000Research

JF - F1000Research

M1 - 1454

ER -

COVID-19 among Indonesian ENT specialist and resident after second dose of Sinovac vaccination

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this